Robert W. Baird restated their neutral rating on shares of Innoviva, Inc. (NASDAQ:INVA) in a research report sent to investors on Thursday. Robert W. Baird currently has a $13.00 target price on the biotechnology company’s stock, up from their prior target price of $11.00.

INVA has been the subject of a number of other research reports. Cowen and Company set a $16.00 price objective on shares of Innoviva and gave the company a buy rating in a report on Monday, May 1st. Zacks Investment Research upgraded shares of Innoviva from a sell rating to a hold rating in a report on Monday, July 17th. Finally, ValuEngine cut shares of Innoviva from a buy rating to a hold rating in a report on Friday, June 2nd. Four research analysts have rated the stock with a hold rating and one has issued a buy rating to the company. The stock has a consensus rating of Hold and an average price target of $14.25.

Shares of Innoviva (NASDAQ:INVA) traded down 0.36% during mid-day trading on Thursday, reaching $13.72. 1,332,337 shares of the company were exchanged. Innoviva has a 12 month low of $8.67 and a 12 month high of $14.55. The stock has a market capitalization of $1.48 billion, a P/E ratio of 17.17 and a beta of 2.56. The firm has a 50-day moving average price of $12.78 and a 200 day moving average price of $12.31.

Innoviva (NASDAQ:INVA) last issued its quarterly earnings data on Wednesday, July 26th. The biotechnology company reported $0.30 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.28 by $0.02. The firm had revenue of $58.60 million during the quarter, compared to analysts’ expectations of $50.53 million. Innoviva had a net margin of 52.56% and a negative return on equity of 27.37%. The business’s revenue for the quarter was up 80.3% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.13 earnings per share. Equities research analysts anticipate that Innoviva will post $1.11 EPS for the current fiscal year.

WARNING: “Robert W. Baird Reaffirms “Neutral” Rating for Innoviva, Inc. (NASDAQ:INVA)” was originally published by Watch List News and is the sole property of of Watch List News. If you are reading this report on another publication, it was copied illegally and republished in violation of United States and international trademark and copyright laws. The legal version of this report can be viewed at https://www.watchlistnews.com/robert-w-baird-reaffirms-neutral-rating-for-innoviva-inc-nasdaqinva/1464533.html.

In other Innoviva news, VP Theodore J. Jr. Witek sold 7,815 shares of the company’s stock in a transaction on Monday, May 22nd. The shares were sold at an average price of $12.01, for a total transaction of $93,858.15. Following the sale, the vice president now directly owns 251,968 shares of the company’s stock, valued at $3,026,135.68. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 1.60% of the company’s stock.

Several institutional investors have recently modified their holdings of INVA. Thrivent Financial for Lutherans bought a new position in shares of Innoviva during the fourth quarter valued at $444,000. Comerica Bank raised its position in shares of Innoviva by 4.5% in the first quarter. Comerica Bank now owns 85,950 shares of the biotechnology company’s stock valued at $1,082,000 after buying an additional 3,673 shares during the last quarter. Trexquant Investment LP bought a new position in shares of Innoviva during the first quarter valued at $818,000. Bank of Montreal Can raised its position in shares of Innoviva by 8,741.8% in the first quarter. Bank of Montreal Can now owns 111,141 shares of the biotechnology company’s stock valued at $1,537,000 after buying an additional 109,884 shares during the last quarter. Finally, BlackRock Inc. raised its position in shares of Innoviva by 68,215.3% in the first quarter. BlackRock Inc. now owns 12,000,259 shares of the biotechnology company’s stock valued at $165,964,000 after buying an additional 11,982,693 shares during the last quarter. 74.99% of the stock is currently owned by institutional investors.

About Innoviva

Innoviva, Inc, formerly Theravance, Inc, is engaged in the development, commercialization and financial management of bio-pharmaceuticals. It focuses on the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate (FF)/vilanterol (VI)) and ANORO ELLIPTA (umeclidinium bromide/vilanterol (UMEC/VI)).

Receive News & Ratings for Innoviva Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innoviva Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.